摘要
上皮性卵巢癌(EOC)的病死率较高,铂耐药是其临床治疗的主要挑战。其耐药机制涉及肿瘤微环境、跨膜物质转运异常、细胞内DNA损伤修复系统功能异常、多种信号通路异常、表观遗传调控等。尽管聚腺苷二磷酸核糖聚合酶抑制剂和抗体药物偶联物等新药的应用改善了部分EOC患者的生存,但耐药复发问题依然存在。未来,需借助多组学技术探索新型生物标志物,并发展针对肿瘤微环境与DNA修复等过程的联合治疗策略,以克服铂耐药,提升疗效。
The mortality rate of epithelial ovarian cancer(EOC)is relatively high,and platinum resistance is the main challenge in its clinical treatment.Its drug resistance mechanism involves abnormal tumor microenvironment,transmembrane material transport,abnormal function of intracellular DNA damage repair system,abnormal multiple signaling pathways,epige-netic regulation,etc.Although the application of new drugs such as polyadenosine diphosphate ribose polymerase inhibitors and antibody-drug conjugates has improved the survival of some EOC patients,the problems of drug resistance and recurrence still exist.In the future,it is necessary to explore new biomarkers with the help of multi-omics technologies and develop combined treatment strategies targeting the tumor microenvironment and processes such as DNA repair,in order to overcome the platinum resistance and improve therapeutic efficacy.
作者
周金金
李国成
ZHOU Jinjin;LI Guocheng(Department of Gynecology,Affiliated Hospital of Yangzhou University,Yangzhou 225000,China)
出处
《医学综述》
2025年第21期2605-2611,2617,共8页
Medical Recapitulate
关键词
上皮性卵巢癌
铂耐药
机制
肿瘤微环境
DNA损伤修复
Epithelial ovarian cancer
Platinum resistance
Mechanism
Tumor microenvironment
DNA damage repair
